Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more
AZ, Amgen rise on asthma data
Tezepelumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) met the primary endpoint of a statistically significant reduction in annualized asthma exacerbation rate in the Phase III NAVIGATOR trial to treat patients with severe, uncontrolled asthma. Shares of both companies gained 3% adding billions in market cap on the readout for the anti-TSLP mAb.
NIH asks clinical researchers to share COVID-19 results promptly
NIH Director Francis Collins encouraged the clinical research community to share COVID-19 clinical trial results as quickly as possible on ClinicalTrials.gov — ahead of regulatory deadlines. NIH is prioritizing the processing of COVID-19 submissions to the website and providing on-on-one support to researchers during the process of submitting results...